Patents by Inventor Doris Apt

Doris Apt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160151478
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: November 16, 2015
    Publication date: June 2, 2016
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 9186397
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: November 17, 2015
    Assignee: Altravax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20150290313
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 15, 2015
    Applicant: Altravax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 8715694
    Abstract: The invention provides polypeptides and virus-like particles having, for example, an ability to induce an immune response to flaviviruses. The polypeptides can include C15, prM, and E polypeptide sequences.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: May 6, 2014
    Assignee: Altravax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20120282287
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: April 16, 2012
    Publication date: November 8, 2012
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 8168772
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: May 1, 2012
    Assignee: Altravax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 8158131
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: April 17, 2012
    Assignee: AltraVax, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20100261660
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
    Type: Application
    Filed: December 22, 2006
    Publication date: October 14, 2010
    Applicant: Maxygen, Inc.
    Inventors: Juha Punnonen, Alexandra Lazetic, Steven R. Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
  • Publication number: 20090311287
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: August 30, 2007
    Publication date: December 17, 2009
    Applicant: Maxygen, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20090181044
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: March 7, 2008
    Publication date: July 16, 2009
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Patent number: 7476390
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: January 13, 2009
    Assignee: Maxygen, Inc.
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20060269566
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
    Type: Application
    Filed: January 13, 2006
    Publication date: November 30, 2006
    Applicant: Maxygen, Inc.
    Inventors: Juha Punnonen, Alexandra Lazetic, Steven Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
  • Publication number: 20050154189
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a human CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind human CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
    Type: Application
    Filed: June 21, 2002
    Publication date: July 14, 2005
    Inventors: Juha Punnonen, Alexandra Lazetic, Steven Leong, Jean Chang, Doris Apt, Claes Gustafsson
  • Publication number: 20050084913
    Abstract: The invention provides novel polypeptides, including novel tumor-associated antigens, and related nucleic acids, vectors, cells, and antibodies. The invention also provides compositions comprising such polypeptides, nucleic acids, vectors, cells, and antibodies, and methods of producing and using the same.
    Type: Application
    Filed: April 19, 2004
    Publication date: April 21, 2005
    Inventors: Juha Punnonen, Doris Apt, Margaret Neighbors, Steven Leong
  • Publication number: 20040110295
    Abstract: The invention relates to nucleic acid vectors useful for expression and production of polypeptides, compositions comprising vectors, and methods for the production and use of vectors and polypeptides.
    Type: Application
    Filed: May 28, 2003
    Publication date: June 10, 2004
    Applicant: Maxygen, Inc., a Delaware corporation
    Inventors: Juha Punnonen, Doris Apt, Robert G. Whalen
  • Publication number: 20040009469
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
    Type: Application
    Filed: February 26, 2003
    Publication date: January 15, 2004
    Applicant: Maxygen, Inc. Patent Department
    Inventors: Doris Apt, Juha Punnonen, Alice M. Brinkman
  • Publication number: 20030190697
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
    Type: Application
    Filed: June 22, 2001
    Publication date: October 9, 2003
    Inventors: Juha Punnonen, Alexandra L.L. Lazetic, Steven R. Leong, Chia-Chun Jean Chang, Doris Apt, Claes Gustafsson
  • Publication number: 20030138881
    Abstract: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
    Type: Application
    Filed: December 20, 2001
    Publication date: July 24, 2003
    Applicant: Maxygen, Inc.
    Inventors: Juha Punnonen, Alexandra Lazetic, Steven R. Leong, Chia-Chun Chang, Doris Apt, Claes Gustafsson
  • Patent number: 6399383
    Abstract: The invention provides human papillomavirus vectors useful in gene therapy. Such a vector contains E1 and E2 coding regions from a benign or low-risk human papillomavirus operably linked to a promoter and enhancer, and an LCR region from a human papillomavirus comprising an origin of replication including binding sites for the E1 and E2 proteins. The invention further provides methods of using such vectors in gene therapy, methods of controlling expression using a patch, and methods of using such vectors to evolve drugs for stimulation of hair growth or alteration of hair color.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: June 4, 2002
    Assignee: Maxygen, Inc.
    Inventors: Doris Apt, Paul Khavari, William P. C Stemmer